Glutathione vs NAC

Glutathione (GSH) is the endogenous master antioxidant of mammalian cells, while N-acetylcysteine (NAC) is a prodrug precursor that replenishes glutathione stores. The choice between direct GSH supplementation and NAC supplementation depends on bioavailability, tissue targeting, and the specific oxidative stress context.

Chemical Identity

Glutathione

Glutathione is a tripeptide (γ-Glu-Cys-Gly) synthesized intracellularly by γ-glutamylcysteine synthetase (GCL) and glutathione synthetase. The γ-linkage between glutamate and cysteine renders GSH resistant to most intracellular peptidases, though it is degraded extracellularly by γ-glutamyl transpeptidase (GGT). Molecular weight: 307.32 g/mol.

N-Acetylcysteine

NAC is the N-acetyl derivative of L-cysteine (MW: 163.19 g/mol). The acetyl group protects the amino moiety from oxidation and improves oral bioavailability. NAC serves as a cysteine donor for de novo glutathione synthesis via the γ-glutamyl cycle.

Bioavailability Comparison

Route	Glutathione	NAC
Oral bioavailability	<5% (hydrolyzed in gut)	~6–10%
IV bioavailability	100%	100%
Nebulized	Limited data	~10–20% (lung)
Liposomal oral	~20–30% (enhanced)	Not applicable

Oral GSH Limitations

Oral glutathione is poorly absorbed intact. The γ-glutamyl bond is cleaved by intestinal GGT and dipeptidases, yielding glutamate, cysteine, and glycine as separate amino acids. Plasma GSH levels show minimal increase after oral GSH ingestion, though some studies report increased erythrocyte GSH. The clinical significance of oral GSH supplementation remains debated.

Liposomal and sublingual formulations claim improved bioavailability, but rigorous pharmacokinetic data are limited. Enterosalivary recycling of GSH may contribute modestly to systemic availability.

NAC Oral Absorption

NAC is well absorbed orally, with peak plasma concentrations reached within 1–2 hours. Approximately 6–10% reaches systemic circulation as intact NAC, with the remainder metabolized to cysteine and sulfate in the intestinal wall and liver. Despite the low bioavailability, NAC effectively raises plasma and tissue cysteine levels, serving as a rate-limiting substrate for glutathione synthesis.

Glutathione Recycling Mechanism

Both exogenous GSH and NAC-derived cysteine feed into the same intracellular recycling system:

1. Synthesis: Glutamate + Cysteine → γ-Glu-Cys (GCL, rate-limiting); γ-Glu-Cys + Gly → GSH (glutathione synthetase)
2. Oxidation: GSH donates electrons to reactive oxygen species (ROS), forming GSSG (oxidized glutathione disulfide)
3. Reduction: Glutathione reductase (GR) reduces GSSG back to 2 GSH using NADPH as the electron donor
4. Degradation: γ-GGT cleaves extracellular GSH to γ-Glu + Cys-Gly; dipeptidase yields Cys + Gly

NAC accelerates this cycle by providing cysteine, the rate-limiting substrate. GCL activity determines the maximum flux through the cycle, and NAC supplementation saturates GCL capacity at high doses.

Clinical Applications

Glutathione Indications

Application	Evidence Level	Route
IV in acetaminophen toxicity	Moderate (adjunct)	IV
IV in cisplatin nephrotoxicity	Moderate	IV
IV in liver disease (NASH)	Preliminary	IV
IV in Parkinson’s disease	Mixed results	IV
Nebulized in pulmonary fibrosis	Preliminary	Nebulized
IV in HIV/AIDS	Limited	IV
IV in male infertility	Limited	IV

NAC Indications

Application	Evidence Level	Route
Acetaminophen overdose (first-line)	Strong	IV/oral
COPD exacerbations	Strong	IV/oral
Contrast-induced nephropathy	Moderate	IV
Psychiatric disorders (OCD, addiction)	Moderate	Oral
Mucolytic (cystic fibrosis)	Strong	Nebulized/oral
NASH/non-alcoholic fatty liver	Moderate	Oral
Pulmonary fibrosis	Moderate	Oral
Sepsis (adjunct)	Preliminary	IV

Dosing Strategies

NAC Dosing

Indication	Dose	Route
Acetaminophen toxicity	150 mg/kg IV over 15 min, then 50 mg/kg over 4 hr, then 100 mg/kg over 16 hr	IV
COPD maintenance	600–1200 mg/day	Oral
Mucolytic	300–600 mg TID	Oral
Psychiatric (adjunct)	1200–3000 mg/day	Oral
Contrast nephropathy	1200 mg before and after contrast	IV

Glutathione Dosing

Indication	Dose	Route
IV antioxidant	600–1200 mg/day	IV
Nebulized (pulmonary)	600 mg BID-TID	Nebulized
Liposomal oral	250–500 mg/day	Oral
IV Parkinson’s	1400 mg/day	IV

Safety Profile

NAC

• GI disturbances (nausea, vomiting, diarrhea) at high doses
• Anaphylactoid reactions with IV administration (rare, attenuated by slow infusion)
• May chelate metals (theoretical concern with concurrent mineral supplementation)
• Sulfurous taste/smell with oral formulations
• Generally well-tolerated at standard doses

Glutathione

• IV GSH may cause flushing, chest tightness (rare)
• Nebulized GSH may trigger bronchospasm in asthmatics
• No established toxicity at standard supplemental doses
• Theoretical concern: high GSH may reduce tumor cell sensitivity to radiation/chemotherapy

Key Differences Summary

Factor	Glutathione	NAC
Mechanism	Direct antioxidant	Cysteine donor / GSH precursor
Oral bioavailability	<5%	~6–10%
Primary clinical use	IV in toxicity/oxidative states	Acetaminophen overdose, mucolytic
Rate-limiting	N/A (supplemental)	Cysteine availability
Cost	Higher (liposomal/IV)	Lower (widely available)
Evidence base	Moderate for IV	Strong for acetaminophen, COPD
Recycling dependency	Requires GR + NADPH	Requires GCL + GR + NADPH

When to Choose Which

NAC is preferred when:

• Oral supplementation is required
• Acetaminophen toxicity is the indication (first-line therapy)
• Mucolytic effect is desired (COPD, CF, bronchitis)
• Cost is a consideration
• Glutathione repletion from precursor supply is sufficient

Glutathione may be preferred when:

• IV administration is feasible
• Direct antioxidant supplementation is indicated
• Cysteine availability is not the rate-limiting factor
• Specific tissue targeting (e.g., nebulized for pulmonary fibrosis) is desired
• Patient cannot tolerate NAC’s side effects

References

1. Atkuri KR, et al. “N-Acetylcysteine — a safe antidote for cysteine/glutathione deficiency.” Curr Opin Pharmacol 2007;7:355-359.
2. Schmitt B, et al. “Oral glutathione supplementation increases erythrocyte glutathione concentration in healthy volunteers.” Free Radic Res 2015;49:1276-1283.
3. Millea PJ. “N-Acetylcysteine: multiple clinical applications.” Am Fam Physician 2009;80:265-269.
4. Trepanier CH, et al. “Glutathione in pulmonary medicine.” Can Respir J 2005;12:213-216.
5. Sinha R, et al. “Assessment of novel glutathione-enhancing formulas.” Clin Pharmacol Drug Dev 2018;7:640-649.